Martin Kieninger1, Michael Gruber2, Isabella Knott2, Katja Dettmer3, Peter J Oefner3, Sylvia Bele4, Christina Wendl5, Simon Tuemmler2, Bernhard Graf2, Christoph Eissnert2. 1. Department of Anesthesiology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. martin.kieninger@ukr.de. 2. Department of Anesthesiology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 3. Institute of Functional Genomics, University of Regensburg, Regensburg, Germany. 4. Department of Neurosurgery, University Hospital Regensburg, Regensburg, Germany. 5. Department of Neuroradiology, University Hospital Regensburg, Regensburg, Germany.
Abstract
BACKGROUND: Oral nimodipine is used for prophylaxis and treatment of delayed cerebral ischemia in patients with aneurysmal or perimesencephalic subarachnoid hemorrhage (SAH). In cases of serious refractory cerebral vasospasm, a continuous intra-arterial (IA) infusion of nimodipine (CIAN) may be required to avoid cerebral ischemia. Nimodipine can cause arterial hypotension requiring either a dosage reduction or its discontinuation. Aim of the present study was to examine the effect of different nimodipine formulations on arterial blood pressure in aneurysmal or perimesencephalic SAH patients and to measure the plasma levels after both, peroral administration as tablet or solution and IA infusion. METHODS: In a prospective setting, over a 1-year observation period, data on the course of arterial blood pressure and nimodipine dosage were collected for 38 patients undergoing treatment for aneurysmal or perimesencephalic SAH in an intensive care unit. In addition, plasma concentrations of nimodipine were measured by liquid chromatography-tandem mass spectrometry. RESULTS: The intended full dose of 60 mg of nimodipine given orally every 4 h could only be administered on 57.2% of the examined days. Ninety-seven episodes of relevant arterial hypotension probably caused by the administration of nimodipine were observed within the first 14 days of treatment. Drops in blood pressure occurred about three times as often after administration of nimodipine as oral solution than as tablet. However, there were no differences in nimodipine plasma levels between the two formulations. In patients suffering from higher-grade SAH, arterial hypotension and consequent dosage reduction or discontinuation of nimodipine were more frequent than in patients with lower-grade SAH. Plasma concentrations of nimodipine during CIAN did not exceed those achieved by oral administration. CONCLUSIONS: Dosage reduction or discontinuation of oral nimodipine is often necessary in patients with higher-grade SAH. Oral nimodipine solutions cause drops in blood pressure more frequently than tablets. Intra-arterial infusion rates of less than 1 mg/h result in venous plasma concentrations of nimodipine similar to those observed after oral application of 60 mg every 4 h.
BACKGROUND: Oral nimodipine is used for prophylaxis and treatment of delayed cerebral ischemia in patients with aneurysmal or perimesencephalic subarachnoid hemorrhage (SAH). In cases of serious refractory cerebral vasospasm, a continuous intra-arterial (IA) infusion of nimodipine (CIAN) may be required to avoid cerebral ischemia. Nimodipine can cause arterial hypotension requiring either a dosage reduction or its discontinuation. Aim of the present study was to examine the effect of different nimodipine formulations on arterial blood pressure in aneurysmal or perimesencephalic SAH patients and to measure the plasma levels after both, peroral administration as tablet or solution and IA infusion. METHODS: In a prospective setting, over a 1-year observation period, data on the course of arterial blood pressure and nimodipine dosage were collected for 38 patients undergoing treatment for aneurysmal or perimesencephalic SAH in an intensive care unit. In addition, plasma concentrations of nimodipine were measured by liquid chromatography-tandem mass spectrometry. RESULTS: The intended full dose of 60 mg of nimodipine given orally every 4 h could only be administered on 57.2% of the examined days. Ninety-seven episodes of relevant arterial hypotension probably caused by the administration of nimodipine were observed within the first 14 days of treatment. Drops in blood pressure occurred about three times as often after administration of nimodipine as oral solution than as tablet. However, there were no differences in nimodipine plasma levels between the two formulations. In patients suffering from higher-grade SAH, arterial hypotension and consequent dosage reduction or discontinuation of nimodipine were more frequent than in patients with lower-grade SAH. Plasma concentrations of nimodipine during CIAN did not exceed those achieved by oral administration. CONCLUSIONS: Dosage reduction or discontinuation of oral nimodipine is often necessary in patients with higher-grade SAH. Oral nimodipine solutions cause drops in blood pressure more frequently than tablets. Intra-arterial infusion rates of less than 1 mg/h result in venous plasma concentrations of nimodipine similar to those observed after oral application of 60 mg every 4 h.
Authors: Jared M Pisapia; Xiangsheng Xu; Jane Kelly; Jamie Yeung; Geneive Carrion; Huaiyu Tong; Sudha Meghan; Omar M El-Falaky; M Sean Grady; Douglas H Smith; Sergei Zaitsev; Vladimir R Muzykantov; Michael F Stiefel; Sherman C Stein Journal: Exp Neurol Date: 2011-11-04 Impact factor: 5.330
Authors: Jens P Dreier; Sebastian Major; Andrew Manning; Johannes Woitzik; Chistoph Drenckhahn; Jens Steinbrink; Christos Tolias; Ana I Oliveira-Ferreira; Martin Fabricius; Jed A Hartings; Peter Vajkoczy; Martin Lauritzen; Ulrich Dirnagl; Georg Bohner; Anthony J Strong Journal: Brain Date: 2009-05-06 Impact factor: 13.501
Authors: Karol P Budohoski; Marek Czosnyka; Peter Smielewski; Magdalena Kasprowicz; Adel Helmy; Diederik Bulters; John D Pickard; Peter J Kirkpatrick Journal: Stroke Date: 2012-11-13 Impact factor: 7.914
Authors: Miriam Weiss; Walid Albanna; Catharina Conzen-Dilger; Nick Kastenholz; Katharina Seyfried; Hani Ridwan; Martin Wiesmann; Michael Veldeman; Tobias Philip Schmidt; Murad Megjhani; Henna Schulze-Steinen; Hans Clusmann; Marinus Johannes Hermanus Aries; Soojin Park; Gerrit Alexander Schubert Journal: Stroke Date: 2022-06-08 Impact factor: 10.170
Authors: Corinne Fischer; Johannes Goldberg; Sonja Vulcu; Franca Wagner; Daniel Schöni; Nicole Söll; Matthias Hänggi; Jörg Schefold; Christian Fung; Jürgen Beck; Andreas Raabe; Werner J Z'Graggen Journal: Front Neurol Date: 2019-10-31 Impact factor: 4.003
Authors: Andreas Kramer; Moritz Selbach; Thomas Kerz; Axel Neulen; Marc A Brockmann; Florian Ringel; Carolin Brockmann Journal: Front Neurol Date: 2022-03-15 Impact factor: 4.003